PMID- 3896457
OWN - NLM
STAT- MEDLINE
DCOM- 19851004
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 56
IP  - 6
DP  - 1985 Sep 15
TI  - Allogeneic bone marrow transplantation for acute leukemia refractory to induction 
      chemotherapy.
PG  - 1374-9
AB  - This article compares the outcome of 14 patients with primary refractory acute 
      leukemia who underwent bone marrow transplantation from human leukocyte antigen 
      (HLA)-identical donors with that of 18 age-matched control patients who received 
      chemotherapy. Complete clearing of leukemia was seen in all 14 transplanted 
      patients. Five of the transplanted patients are alive 98 to 1790 days 
      posttransplant, and four are free of leukemia. Nine patients have died, eight 
      with severe graft-versus-host disease associated with interstitial pneumonia or 
      systemic infections and one with relapse from chemotherapy-associated infections. 
      Engraftment was seen in all patients. Severe graft-versus-host disease (grades 
      III and IV) was seen in ten patients and resolved in three patients following 
      high-dose corticosteroid treatment. Three of the 18 control patients are alive, 
      none of them in complete remission. It appears that the combination of 
      piperazinedione and total-body irradiation followed by allogeneic transplant is 
      effective induction treatment for primary refractory acute leukemia and will be 
      considered in the future as first salvage treatment for patients failing 
      induction treatment.
FAU - Zander, A R
AU  - Zander AR
FAU - Dicke, K A
AU  - Dicke KA
FAU - Keating, M
AU  - Keating M
FAU - Vellekoop, L
AU  - Vellekoop L
FAU - Culbert, S
AU  - Culbert S
FAU - Spitzer, G
AU  - Spitzer G
FAU - Kanojia, M
AU  - Kanojia M
FAU - Jagannath, S
AU  - Jagannath S
FAU - Schell, S
AU  - Schell S
FAU - Hester, J
AU  - Hester J
AU  - et al.
LA  - eng
GR  - CA-23077/CA/NCI NIH HHS/United States
GR  - CA-28153/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Piperazines)
RN  - 64474-15-3 (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - *Bone Marrow Transplantation
MH  - Female
MH  - Humans
MH  - Leukemia/drug therapy/mortality/*therapy
MH  - Male
MH  - Piperazines/therapeutic use
MH  - Whole-Body Irradiation
EDAT- 1985/09/15 00:00
MHDA- 1985/09/15 00:01
CRDT- 1985/09/15 00:00
PHST- 1985/09/15 00:00 [pubmed]
PHST- 1985/09/15 00:01 [medline]
PHST- 1985/09/15 00:00 [entrez]
AID - 10.1002/1097-0142(19850915)56:6<1374::aid-cncr2820560626>3.0.co;2-c [doi]
PST - ppublish
SO  - Cancer. 1985 Sep 15;56(6):1374-9. doi: 
      10.1002/1097-0142(19850915)56:6<1374::aid-cncr2820560626>3.0.co;2-c.